Keiji Furuuchi
Overview
Explore the profile of Keiji Furuuchi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
730
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nesic K, Rybinski K, Ratnayake G, Ho G, Lim R, Radke M, et al.
Clin Transl Med
. 2025 Mar;
15(3):e70274.
PMID: 40074693
No abstract available.
2.
Koganemaru S, Fuchigami H, Morizono C, Shinohara H, Kuboki Y, Furuuchi K, et al.
Mol Cancer Ther
. 2024 Oct;
24(2):242-250.
PMID: 39450538
Antibody-drug conjugates (ADC) are a rapidly advancing category of therapeutic agents with notable anticancer efficacy. However, the emergence of interstitial lung disease as a severe ADC-associated adverse event highlights the...
3.
Wang Y, Xia B, Cao L, Yang J, Feng C, Jiang F, et al.
Antib Ther
. 2024 Jul;
7(3):221-232.
PMID: 39036069
Background: Several HER2-targeting antibody-drug conjugates (ADC) have gained market approval for the treatment of HER2-expressing metastasis. Promising responses have been reported with the new generation of ADCs in patients who...
4.
Sakai H, Kawakami H, Teramura T, Onodera Y, Somers E, Furuuchi K, et al.
Clin Transl Med
. 2021 Jun;
11(6):e454.
PMID: 34185411
Background: The main function of folate receptor α (FOLRα) has been considered to mediate intracellular folate uptake and induce tumor cell proliferation. Given the broad spectrum of expression among malignant...
5.
Shimizu T, Fujiwara Y, Yonemori K, Koyama T, Sato J, Tamura K, et al.
Clin Cancer Res
. 2021 Apr;
27(14):3905-3915.
PMID: 33926914
Purpose: MORAb-202, an antibody-drug conjugate containing farletuzumab and eribulin with a cathepsin-B cleavable linker, targets folate receptor α (FRα)-expressing tumor cells. The primary objective of this first-in-human study was to...
6.
Furuuchi K, Rybinski K, Fulmer J, Moriyama T, Drozdowski B, Soto A, et al.
Cancer Sci
. 2021 Mar;
112(6):2467-2480.
PMID: 33756060
The antibody-drug conjugate (ADC) MORAb-202, consisting of farletuzumab paired with a cathepsin B-cleavable linker and eribulin, targets folate receptor alpha (FRA), which is frequently overexpressed in various tumor types. MORAb-202...
7.
Cheng X, Li J, Tanaka K, Majumder U, Milinichik A, Verdi A, et al.
Mol Cancer Ther
. 2018 Sep;
17(12):2665-2675.
PMID: 30262588
Microtubule-targeting agents (MTA) have been investigated for many years as payloads for antibody-drug conjugates (ADC). In many cases, these ADCs have shown limited benefits due to lack of efficacy or...
8.
Rybinski K, Imtiyaz H, Mittica B, Drozdowski B, Fulmer J, Furuuchi K, et al.
Oncotarget
. 2015 Sep;
6(28):25429-40.
PMID: 26327620
Over-expression of endosialin/CD248 (herein referred to as CD248) has been associated with increased tumor microvasculature in various tissue origins which makes it an attractive anti-angiogenic target. In an effort to...
9.
Zhou Z, Tone Y, Song X, Furuuchi K, Lear J, Waldmann H, et al.
Proc Natl Acad Sci U S A
. 2008 Jan;
105(2):641-5.
PMID: 18178614
Glucocorticoid-induced TNF receptor ligand (GITRL) is a member of the TNF super family (TNFSF). GITRL plays an important role in controlling regulatory T cells. The crystal structure of the mouse...
10.
Tone Y, Furuuchi K, Kojima Y, Tykocinski M, Greene M, Tone M
Nat Immunol
. 2007 Dec;
9(2):194-202.
PMID: 18157133
The transcription factor Foxp3 is involved in the differentiation, function and survival of CD4+CD25+ regulatory T (T(reg)) cells. Details of the mechanism underlying the induction of Foxp3 expression remain unknown,...